Story perspectives

China Leads in Rare Disease Treatment and Governance

11/5/2025

40 8

Summary

Story summary

China is advancing in rare disease governance and becoming a key player, says Marc Dunoyer of AstraZeneca.
It has built a comprehensive ecosystem for rare diseases aligned with Healthy China 2030.
The national rare disease catalog lists 207 conditions, with almost 100 therapies covered by insurance.
AstraZeneca has invested in China, launching therapies and opening a Beijing research center.
Dunoyer notes affordability remains a challenge for many rare disease families.

1 of 1

Story summary

China is advancing in rare disease governance and becoming a key player, says Marc Dunoyer of AstraZeneca.
It has built a comprehensive ecosystem for rare diseases aligned with Healthy China 2030.
The national rare disease catalog lists 207 conditions, with almost 100 therapies covered by insurance.
AstraZeneca has invested in China, launching therapies and opening a Beijing research center.
Dunoyer notes affordability remains a challenge for many rare disease families.